In the treatment of Alzheimer’s disease (AD), health care professionals are in dire need of clinical confidence in the evidence-based potential of novel disease-modifying therapeutic options. Several promising classes of emerging agents such as amyloid-targeting humanized monoclonal antibodies (mAbs), incretin-based …
Dementia is most commonly caused by Alzheimer’s disease (AD), a multifactorial progression of neurodegeneration in which the accumulation of amyloid-beta and tau proteins in the brain and chronic and dysregulated inflammatory processes lead to significant cognitive impairment. Though novel diagnostic …
Interleukin (IL)-23 has been identified as a main driver of inflammation in the pathology of inflammatory bowel disease (IBD). While all agents in this anti-IL-23 class neutralize IL-23 by binding of the Fab fragment, differences in Fc fragment may be …
Up to 80% of patients with Crohn’s disease (CD) report some degree of bowel urgency, a symptom that not only significantly adds to their overall emotional and social burden but can be an indicator of uncontrolled bowel inflammation. Unfortunately, bowel …
Immune checkpoint inhibitors (ICIs), PARP inhibitors, VEGF inhibitors, kinase inhibitors, and chemotherapy are all being used in various combinations for the treatment of endometrial and ovarian cancers. As these new combinations seek to further improve and enhance the efficacy of …
The treatment landscape for hemophilia A and B is expanding with strategies and therapies to optimize efficacy, provide durable hemostasis restoration, and improve safety. These contemporary approaches to care have also led to new pathways and assays for clinical and …
More than 80% of patients with ulcerative colitis (UC), including those receiving treatment, experience bowel urgency. This symptom dramatically impacts patient quality of life (QoL) and can lead to depression, social isolation, disruption with work, interference with relationships, and fatigue. …
Due to the rising prevalence and significant burden of Alzheimer’s disease there is a critical need for continuing education aimed at bridging existing gaps in clinician knowledge, competence, and performance concerning novel and emerging amyloid-targeting therapies (ATTs), especially in the …
Data from recent clinical trials for first-line combination options using immunotherapies for ovarian cancer (OC) can be challenging for clinicians with no experience selecting patients for combinatorial treatment approaches or using combination therapies for their patients. During this podcast, Drs. …